GlassScriptPhysician profile
Radha Rishi
NPI 1386673416
$13,305.46
in general payments reported to CMS, 2019-2025
35 companies · $4,717 in 2025
The $4,717 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $786 · 2021: $1,520 · 2022: $1,786 · 2023: $1,522 · 2024: $1,962 · 2025: $4,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,626 · Consulting Fee: $1,462 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,625.51 |
| Consulting Fee | $1,461.55 |
| Education | $114.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,304.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,864.25 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $1,499.62 | 2019-2025 | Haegarda, Hizentra, Privigen |
| Glaxosmithkline, LLC. | $1,283.32 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $914.53 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $834.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $644.83 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Genentech USA, INC. | $623.19 | 2019-2025 | Xolair |
| Grifols USA, LLC | $456.32 | 2019-2025 | Xembify |
| Biocryst US Sales Co., LLC | $448.16 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $439.46 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $243.35 | 2020-2022 | |
| Optinose US, INC. | $192.25 | 2019-2023 | |
| Cycle Pharmaceuticals INC | $154.50 | 2025 | Sajazir |
| Shire North American Group INC | $144.98 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.49 | 2019-2022 | |
| Bio Products Laboratory USA, INC. | $125.01 | 2022-2023 | Coagadex, Gammaplex |
| Sanofi-Aventis U.S. LLC | $116.41 | 2019-2025 | |
| Pharming Healthcare, INC. | $110.98 | 2020-2024 | Ruconest |
| Covis Pharma Gmbh | $96.90 | 2021 | |
| Octapharma USA, INC. | $92.99 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $92.74 | 2019-2022 | |
| Incyte Corporation | $91.78 | 2021-2025 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $62.80 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $54.11 | 2025 | Dawnzera |
| Galderma Laboratories, L.P. | $44.11 | 2025 | Nemluvio |
| Abbvie INC. | $42.60 | 2022-2023 | Rinvoq |
| Biocryst Pharmaceuticals, INC. | $36.05 | 2020 | |
| Blueprint Medicines Corporation | $33.79 | 2025 | Ayvakit |
| Adma Biomanufacturing LLC | $33.28 | 2020-2025 | |
| Lilly USA, LLC | $24.99 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $22.50 | 2023 | |
| Eyevance Pharmaceuticals LLC | $17.07 | 2021 | |
| Amgen INC. | $14.89 | 2025 | Tezspire |
| Aimmune Therapeutics, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radha Rishi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.